$LEGN News
Last published 1d ago
- 1d agoLEGNLegend Biotech Reports Third Quarter 2026 Results and Recent HighlightsGlobeNewswireCARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million Half of...
- 2d agoLEGNGILDAZNMCK+4Gabelli Releases Agenda for 8th Annual Healthcare SymposiumGlobeNewswirePALM BEACH, Florida, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Gabelli today released the agenda for its 8th Annual Healthcare Symposium to be held this Friday, November 13 in conjunction with Columbia Business School at the
- 1w agoLEGNLegend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026GlobeNewswireNew CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatmentUpdated data to be presented from first-in-human trial of LB2501, an investigational,
- 2w agoLEGNLegend Biotech to Host Investor Conference Call on Third Quarter 2026 ResultsGlobeNewswireBRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday,
- 2w agoLEGNGILDAZNMCK+5Gabelli To Host 8th Annual Healthcare SymposiumGlobeNewswirePALM BEACH, Florida, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting the 8th Annual Healthcare Symposium in conjunction with Columbia Business School on Friday, November 13, 2026, at the Paley Center in New York.
- 3w agoLEGNLegend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T TherapyGlobeNewswireLB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T
- 1mo agoLEGNLegend Biotech Appoints Ingrid Zhang as Chief Executive OfficerGlobeNewswireBRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of
- 2mo agoLEGNLegend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual MeetingGlobeNewswireUpdated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapyReal-world evidence and post-authorization safety
- 2mo agoLEGNLegend Biotech to Participate in the Morgan Stanley Global Healthcare ConferenceGlobeNewswireBRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will
- 3mo agoLEGNLegend Biotech Reports Second Quarter 2026 Financial Results - LEGEND BIOTECH CORPEarnings Call TranscriptsGood day, everyone, and thank you for standing by. Welcome to Legend Biotech second quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a
- 3mo agoLEGNLegend Biotech Reports Second Quarter 2026 Results and Recent HighlightsGlobeNewswireCARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 millionExpanded CARVYKTI® availability to 348 global sites and 19 global markets with
- 3mo agoLEGNLegend Biotech to Host Investor Conference Call on Second Quarter 2026 ResultsGlobeNewswireBRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday,
- 3mo agoLEGNLegend Biotech Announces CEO TransitionGlobeNewswireYing Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transitionAlan Bash, current President of the CARVYKTI Business
- 4mo agoCLDILEGNRARECalidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of DirectorsGlobeNewswireSAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines,
- 4mo agoLEGNLegend Biotech Corporation Announces Pricing of Public OfferingGlobeNewswireBRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced the pricing of an underwritten public
- 4mo agoLEGNLegend Biotech Corporation Announces Proposed Public OfferingGlobeNewswireBRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that it has commenced an underwritten
- 5mo agoLEGNLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin LymphomaGlobeNewswireAchieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 studySingle infusion of LB2501 generated dose-dependent in vivo CAR-T
- 5mo agoLEGNLegend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)GlobeNewswirePromising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy, as an off-the-shelf, single-infusion treatment for B‑cell malignanciesAn ORR of 100% (6/6) was observed in the
- 5mo agoLEGNLegend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026GlobeNewswireLB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of 28.6% and a DCR of
- 5mo agoLEGNLegend Biotech Announces Presentations at ASCO 2026GlobeNewswirePreliminary results from Phase 1 data for LB2102 to reinforce early evidence of activity in solid tumors in a rapid oral presentation New data from the CARTITUDE-4 study to highlight a cytogenetic subgroup analysis of
- 6mo agoLEGNLegend Biotech Reports First Quarter 2026 Results and Recent HighlightsGlobeNewswireCARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately $597 millionCARVYKTI® now available across 18 global markets, following recent
- 6mo agoLEGNLegend Biotech Expands Scientific Advisory Expertise to Inform Future GrowthGlobeNewswireSOMERSET, N.J., May 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the engagement with a group of distinguished scientific
- 6mo agoLEGNLegend Biotech to Host Investor Conference Call on First Quarter 2026 ResultsGlobeNewswireSOMERSET, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 12,
- 8mo agoLEGNLegend Biotech Reports Fourth Quarter 2025 Financial ResultsLEGEND BIOTECH CORPEarnings Call TranscriptsGood day, and welcome to the Legend 4th Quarter 2025 Earnings Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Instructions will
- 8mo agoLEGNLegend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent HighlightsGlobeNewswireCARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $555 million and $1.9 billion for the fourth quarter and full year 2025, respectivelySurpassed milestone of more than 10,000 patients
- 8mo agoLEGNLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 ResultsGlobeNewswireSOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March
- 9mo agoLEGNLegend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier UseGlobeNewswireSix poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan. 21, 2026
- 10mo agoLEGNLegend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireExceeded 10,000 patients treated to date with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell
- 10mo agoLEGNLegend Biotech to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive
- 11mo agoLEGNLegend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025GlobeNewswireTriple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI® Translational analyses show stronger immune
- 11mo agoLEGNLegend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & TradeGlobeNewswireRecognizes the company's continued investment and expansion of cell therapy manufacturing and R&D operations in Ghent, reinforcing Flanders' position as a global biotech hub SOMERSET, N.J. and GHENT, Belgium, Nov.
- 12mo agoLEGNLegend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in PhiladelphiaGlobeNewswire31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation The facility will support CAR-T R&D in potential oncology and immunology
- 12mo agoLEGNLegend Biotech Reports Third Quarter 2025 Results and Recent HighlightsGlobeNewswireCARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 millionEC and U.S. FDA label updates for CARVYKTI® to include overall survival benefit versus standard of care Over 9,000
- 1y agoLEGNLegend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswireTwo oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET,
- 1y agoLEGNLegend Biotech to Host Investor Conference Call on Third Quarter 2025 ResultsGlobeNewswireSOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Wednesday,
- 1y agoAKROEXELLEGNSynOx Therapeutics Strengthens Board of Directors with Leading Experts in Commercialisation and Corporate Development Amid Continued Corporate ProgressGlobeNewswireDUBLIN and OXFORD, United Kingdom and PHILADELPHIA, Oct. 21, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited ("SynOx"), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant
- 1y agoLEGNLegend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoLEGNLegend Biotech to Participate in the Morgan Stanley Global Healthcare ConferenceGlobeNewswireSOMERSET, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive
- 1y agoLEGNLegend Biotech Appoints Carlos Santos as Chief Financial OfficerGlobeNewswireSOMERSET, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief
- 1y agoLEGNLegend Biotech Corporation (LEGN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoLEGNLegend Biotech Reports Second Quarter 2025 Results and Recent HighlightsGlobeNewswireCARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $439 millionCARVYKTI® demonstrated positive long-term outcomes in CARTITUDE-1 study with one-third of patients remaining
- 1y agoLEGNLegend Biotech to Host Investor Conference Call on Second Quarter 2025 ResultsGlobeNewswireSOMERSET, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, August
- 1y agoLEGNLegend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual MeetingGlobeNewswireOral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years
- 1y agoLEGNLegend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCTGlobeNewswireAn oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® infusion New
- 1y agoLEGNLegend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswireSOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00
- 1y agoLEGNLegend Biotech Reports First Quarter 2025 Results and Recent HighlightsGlobeNewswireCARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived
- 1y agoLEGNLegend Biotech to Host Investor Conference Call on First Quarter 2025 ResultsGlobeNewswireSOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13,
- 1y agoLEGNLegend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent HighlightsGlobeNewswireCARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at
- 1y agoLEGNLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 ResultsGlobeNewswireSOMERSET, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March
- 1y agoLEGNLegend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireSOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive